Table 1.
Duration and disutility of treatment-related adverse events (TRAEs)
| Period (days) | Disutility |
QALY
impact |
Reference
for duration |
Reference
for disutility |
||
|---|---|---|---|---|---|---|
| TRAE | ||||||
| Infusion-related reaction | 5 | -0.011 | -0.0002 | 39 | 34 | |
| PML | 93.1 | -0.200 | -0.0510 | * | 39 | |
| Infection (severe events) | 14 | -0.190 | -0.0073 | ** | 48 | |
| Autoimmune thyroid-related event | 365.25 | -0.110 | -0.1100 | 39 | 39 | |
| Influenza-like symptoms | 7 | -0.210 | -0.0040 | *** | 49 | |
| Malignancy | 365.25 | -0.116 | -0.1160 | 35 | 35 | |
| Immune thrombocytopenic purpura | 28 | -0.090 | -0.0069 | 39 | 39 | |
QALY: Quality adjusted life year; TRAE: Treatment-related adverse events; PML: Progressive multifocal leukoencephalopathy
*Based on steroid therapy duration for PML-related immune reconstitution syndrome, **Based on the assumption that most therapies for severe infections are taken for about two weeks, ***Based on the assumption that influenza symptoms persist for about seven days.